Mizuho Securities Reiterates Buy on Jazz Pharmaceuticals (JAZZ) Following Dinner Takeaway
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Mizuho Securities reiterated a Buy rating and $185.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) after hosting a dinner with the company.
Analyst Irina Koffler commented, "We hosted a dinner for Jazz on Sept 13. We believe that the company is working to strengthen its defenses in the Xyrem generic litigation via its 2033 Valproate patents while simultaneously advancing an intriguing life cycle extension, diversifying revenues via M&A, and aggressively repurchasing stock. Shares may remain range-bound ahead of meaningful developments in the Xyrem litigation, but we note that settlement can occur at any time."
Shares of Jazz Pharmaceuticals closed at $122.54 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- New Oriental Education (EDU) PT Raised to $60 at Brean Capital
- Jefferies Cuts Price Target on Waters Corp. (WAT) Following Revenue Miss
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesIrina Koffler
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!